Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991

被引：0
作者：
Sheppard, Karen E. [1 ]
Foo, Allen [1 ]
Young, Richard [1 ]
Waldeck, Kelly [1 ]
Pearson, Richard [1 ]
McArthur, Grant [1 ]
Christensen, James [2 ]
机构：
[1] Peter MacCallum Canc Ctr, East Melbourne, Australia
[2] Pfizer Oncol, Global Res & Dev, San Diego, CA USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-3416
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3416
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib
    Gong Xueqian
    Chio, Li-Chun
    Webster, Yue
    Lallena, Maria Jose
    Boehnke, Karsten
    Torres, Raquel
    Iversen, Phil
    De Dios, Alfonso
    Smith, Ian
    Reinhard, Christoph
    Peng, Sheng-Bin
    Dempsey, Jack
    Burke, Teresa
    Chen, Shih-Hsun
    Stewart, Trent
    Beckmann, Richard
    Wu, Wenjuan
    Buchanan, Sean G.
    MOLECULAR CANCER RESEARCH, 2016, 14
  • [32] Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
    Young, Richard J.
    Waldeck, Kelly
    Martin, Claire
    Foo, Jung H.
    Cameron, Donald P.
    Kirby, Laura
    Do, Hongdo
    Mitchell, Catherine
    Cullinane, Carleen
    Liu, Wendy
    Fox, Stephen B.
    Dutton-Regester, Ken
    Hayward, Nicholas K.
    Jene, Nicholas
    Dobrovic, Alexander
    Pearson, Richard B.
    Christensen, James G.
    Randolph, Sophia
    McArthur, Grant A.
    Sheppard, Karen E.
    PIGMENT CELL & MELANOMA RESEARCH, 2014, 27 (04) : 590 - 600
  • [33] Preclinical head-to-head comparison of CDK4/6 inhibitor activity toward CDK4 vs CDK6
    Delach, Scott
    Caponigro, Giordano
    CANCER RESEARCH, 2021, 81 (04)
  • [34] Biomarkers for CDK4/6 inhibitor efficacy
    Sorscher, Steven
    BREAST JOURNAL, 2021, 27 (01) : 103 - 103
  • [35] Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs
    Green, Jennifer L.
    Okerberg, Eric S.
    Sejd, Josilyn
    Palafox, Marta
    Monserrat, Laia
    Alemayehu, Senait
    Wu, Jiangyue
    Sykes, Maria
    Aban, Arwin
    Serra, Violeta
    Nomanbhoy, Tyzoon
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (04) : 771 - 779
  • [36] Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia
    Nemoto, Atsushi
    Saida, Satoshi
    Kato, Itaru
    Kikuchi, Jiro
    Furukawa, Yusuke
    Maeda, Yasuhiro
    Akahane, Koshi
    Honna-Oshiro, Hiroko
    Goi, Kumiko
    Kagami, Keiko
    Kimura, Shinya
    Sato, Yuko
    Okabe, Seiichi
    Niwa, Akira
    Watanabe, Kenichiro
    Nakahata, Tatsutoshi
    Heike, Toshio
    Sugita, Kanji
    Inukai, Takeshi
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (01) : 94 - 105
  • [37] Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma
    Mahgoub, T.
    Eustace, A. J.
    Collins, D. M.
    Walsh, N.
    O'Donovan, N.
    Crown, J.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (03) : 900 - 908
  • [38] Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib
    Torres-Guzman, Raquel
    Baquero, Carmen
    Patricia Ganado, Maria
    Marugan, Carlos
    Bian, Huimin
    Zeng, Yi
    Rama, Ramon
    Du, Jian
    Jose Lallena, Maria
    CANCER RESEARCH, 2020, 80 (16)
  • [39] Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
    Leonard, John P.
    LaCasce, Ann S.
    Smith, Mitchell R.
    Noy, Ariela
    Chirieac, Lucian R.
    Rodig, Scott J.
    Yu, Jian Q.
    Vallabhajosula, Shankar
    Schoder, Heiko
    English, Patricia
    Neuberg, Donna S.
    Martin, Peter
    Millenson, Michael M.
    Ely, Scott A.
    Courtney, Rachel
    Shaik, Naveed
    Wilner, Keith D.
    Randolph, Sophia
    Van den Abbeele, Annick D.
    Chen-Kiang, Selina Y.
    Yap, Jeffrey T.
    Shapiro, Geoffrey I.
    BLOOD, 2012, 119 (20) : 4597 - 4607
  • [40] Genetic aberrations in the CDK4 pathway and association with innate resistance to PD-1 blockade in acral melanoma
    Yu, Jiayi
    Kong, Yan
    Chi, Zhihong
    Tang, Bixia
    Sheng, Xinan
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345